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Abstract: The objective of our investigation was to design a self-microemulsifying drug-delivery 
system (SMEDDS) to improve the bioavailability of probucol. SMEDDS was composed of 
probucol, olive oil, Lauroglycol FCC, Cremophor EL, Tween-80, and PEG-400. Droplet sizes 
were determined. In vitro release was investigated. Pharmacokinetics and bioavailability of 
probucol suspension, oil solution, and SMEDDS were evaluated and compared in rats. Plasma drug 
concentration was determined by high-performance liquid chromatography. After administration 
of probucol suspension, plasma drug concentration was very low. Relative bioavailability of 
SMEDDS was dramatically enhanced in an average of 2.15- and 10.22-fold that of oil solution and 
suspension, respectively. It was concluded that bioavailability of probucol was enhanced greatly 
by SMEDDS. Improved solubility and lymphatic transport may contribute to the enhancement 
of bioavailability.
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Introduction
Probucol, a chemical compound with a bisphenol structure, was originally synthesized 
as an antioxidant by Consolidation Coal Company and screened at Dow Chemical 
Company for its ability to reduce serum cholesterol.1 Probucol has been used widely 
in clinical practice for the prevention of the progression of atherosclerosis because 
this agent acts as a potent antioxidant in addition to having a lipid-lowering action.2 In 
  addition, probucol can stop progression of atherosclerotic plaques in carotid arteries.3
However, probucol is slightly absorbed in the gastrointestinal tract due to its poor 
solubility in water (the logP was reported to be 10.91).4 The oral bioavailability of 
probucol is very low. From studies in rats, dogs, and monkeys, it is known that probucol 
accumulates slowly in adipose tissue. Approximately 90% of probucol administered 
orally is unabsorbed.5
Research has been focused on enhancing the solubility of poorly water-soluble 
drugs to improve their oral bioavailability. One of the most popular approaches is lipid-
based formulation, such as oils, surfactant dispersions, self-emulsifying formulations, 
emulsions, and liposomes.6
Self-microemulsifying drug-delivery systems are mixtures of drugs, lipids, surfac-
tants, and cosurfactants, which form a fine oil-in-water (O/W) microemulsion with a 
droplet size of less than 100 nm when exposed to aqueous media under conditions of 
gentle agitation or digestive motility that would be encountered in the gastrointestinal 
(GI) tract. SMEDDS has recently emerged as one of the most interesting approaches to 
improve oral absorption for poorly water-soluble drugs.7,8 The advantages of SMEDDS 
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include ease of production, enhanced solvent capacity, 
increased stability, and the potential to administer the final 
product as an oral soft gelatin cap.9 The commercially avail-
able formulation cyclosporine (NeoralTM) is a microemul-
sion preconcentrate with improved oral bioavailability and 
reduced inter- and intra-subject variability compared to the 
original crude emulsion product, SandimmuneTM.10 Similar 
lipid-based formulations of the human immunodeficiency 
virus (HIV) protease inhibitors, saquinavir, ritonavir, and 
amprenavir, have also reached the market.6 To date, probucol 
formulated in SMEDDS has not yet been evaluated.
The objectives of our present study were to prepare, and 
characterize a SMEDDS formulation of probucol, and assess 
its oral absorption in rats.
Materials and methods
Materials
Probucol was purchased from Qihe Jinzhun Technology Co, 
Ltd, (Shandong, China). Olive oil, PEG-400, Tween-80, and 
n-hexane were purchased from Sinopharm Chemical Reagent 
Co, Ltd, (Shanghai, China). Lauroglycol FCC was kindly 
donated by Gattefosse S.A (Saint-Priest, France).   Cremophor 
EL was kindly provided by BASF Corp. (Washington, NJ). 
Retinyl acetate was purchased from Sigma Chemical Co. 
(St Louis, MO). Acetonitrile (high-pressure liquid chromatogra-
phy [HPLC] grade) was supplied by Burdick and   Jackson Corp. 
(Muskegon, MI). Deionized water was prepared by an Aquapro 
purification system (Chongqing Yiyang Co Ltd, Chongqin, 
China). All other chemicals were analytical grade.
Animals
Male Sprague-Dawley (SD) rats (230 ± 20 g) and imprinting 
control region (ICR) mice (20 ± 2 g), supplied by Depart-
ment of Experimental Animals, Fudan University   (Shanghai, 
China), were acclimated at 25°C and 55% of humidity 
under natural light/dark conditions for 1 week before the 
  experiment. All animal experiments were carried out in 
accordance with guidelines evaluated and approved by the 
ethics committee of Fudan University.
Preparation of SMEDDS formulations
Probucol SMEDDS was composed of olive oil (13%, w/w), 
Lauroglycol FCC (27%, w/w), Cremophor EL (20%, w/w), 
Tween-80 (20%, w/w), and PEG-400 (20%, w/w).   Preparation 
of probucol SMEDDS was simply by mixing the   components. 
Since probucol was difficult to dissolve, it was better to 
dissolve probucol first in Lauroglycol FCC. Olive oil, 
Cremophor EL, and PEG-400 were then added slowly with 
gentle stirring until a homogeneous mixture formed. The 
mixture was sealed in a glass vial and stored under room 
temperature.
Droplet size
One gram of SMDROPLET SIZEEDDS was diluted in 
250 mL of deionized water, phosphate-buffered saline (PBS; 
pH 7.0), and 0.1 M hydrochloride solution,   respectively. The 
solution was inverted and shaken gently to mix   thoroughly. 
The droplet size of microemulsion was determined by 
NicompTM 380 ZLS laser diffraction sizer (PSS Nicomp, 
Santa Barbara, CA). The measurement conditions were: 
He–Ne laser; angle, 90°; temperature, 23°C; reflection 
index, 1.333; wavelength, 632.8 nm; or with adjustment if 
needed.
In order to determine the effects of different media and 
dilution volume on the droplet size of microemulsion, 1 g of 
SMEDDS was added into 10 mL, 20 mL, 50 mL, 100 mL, 
250 mL, and 500 mL of deionized water, PBS (pH 7.0), and 
0.1 M hydrochloride solution, respectively, and the resulting 
solutions were slightly shaken. The droplet sizes of these 
solutions were analyzed.
The effect of drug loading on droplet size in different 
media was studied. Five milligrams, 10 mg, 20 mg, 40 mg, 
and 60 mg of probucol were added to 1 g of blank SMEDDS. 
These probucol-loading SMEDDS were diluted to 250 mL 
deionized water, PBS (pH 7.0), and 0.1 M hydrochloride 
solution, respectively, and the droplet sizes of resulted 
  solutions were determined.
Morphology
The morphology of SMEDDS was observed using a trans-
mission electron microscope (TEM; CM120; Philips Co, 
Amsterdam, The Netherlands). SMEDDS was diluted with 
deionized water at 1:50 and mixed by slight shaking. One 
drop of diluted samples was deposited on a film-coated 
copper grid and then stained with one drop of 2% aqueous 
solution of phosphotungstic acid (PTA), and allowed to dry 
before observation under the electron microscope.
Dissolution studies
In  order  to  compare  the  dissolution  behaviors  of 
  probucol-loaded SMEDDS and crude probucol, PBS (pH 7.0) 
and 0.1 M hydrochloride solution were chosen as the dissolu-
tion media. Dissolution studies were performed according to 
the method described previously.11
SMEDDS containing 60 mg of probucol or 60 mg of crude 
probucol was filled in hard gelatin capsules and   introduced 
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into 200 mL of a dissolution medium maintained at 37°C. The 
revolution speed of the paddle was kept constant at 100 rpm. 
Aliquot of 5 mL was withdrawn at 0, 10, 20, 30, 40 and 
60 minutes, and filtered through 0.45 µm membrane filters. 
The concentration of probucol was determined by HPLC. 
The removed volume was replaced each time with 5 mL of 
fresh medium.
Bioavailability study
Bioavailability of probucol SMEDDS was compared with 
probucol suspension and olive oil solution. Rats were fasted 
overnight before experiment with free access to water. 
Probucol suspension (probucol dispersed in 1% [w/v] 
  carboxymethyl cellulose–Na solution), probucol dissolved in 
olive oil and probucol-loaded SMEDDS (60 mg/kg of body 
weight) were given to the rats by intragastric administration, 
respectively. About 0.8 mL of blood sample was collected 
into heparinized tubes at 0.5, 1, 2, 4, 5, 6, 8, 12, 24, 48, 96, 
and 120 hours. Blood samples were centrifuged at 10,000 
rpm for 10 minutes and plasma samples were collected and 
stored at -18°C.
Determination of probucol in rat plasma 
by RP-hPLC
All samples were analyzed by a modified HPLC/UV method. The 
HPLC system consisted of a LC-10AT pump, a SPD-10A UV 
detector (Shimadzu, Kyoto, Japan), and a data-processing 
system (N2000, YingPu Co Ltd, Hangzhou, China). Probucol 
was separated by a C18 column (5 µm, 4.6 mm × 150 mm; 
  Phenomenex, Torrance, CA) guarded with a refillable pre-
column (C18, 2.0 mm × 20 mm; Phenomenex, Torrance, CA) 
at room temperature. Probucol was detected at 242 nm. The 
mobile phase was a mixture of acetonitrile: H2O (96:4, v/v) and 
was delivered at a flow rate of 1 mL ⋅ minute-1.12
Liquid–liquid plasma extraction procedure was used as 
follows: in a 5 mL tube, 300 µL plasma was added, followed 
by 10 µL of internal standard (50 µg ⋅ mL-1 of retinyl acetate) 
solution, and vortex mixed for 30 seconds. Then 150 µL of 
ethanol and 200 µL of methanol were added to precipitate 
the protein. Then 1 mL of hexane was added and vortexed for 
3 minutes. After centrifuging at 12,000 rpm for 10 minutes, 
the upper layer was transferred to another tube and evaporated 
under a light stream of nitrogen at 40°C. The residue was dis-
solved by 100 µL of mobile phase and 20 µL was injected 
for HPLC analysis. Quantification was based on area ratio 
of probucol and the internal standard.13
The retention times for internal standard and probucol 
were about 6.7 minutes and 11.0 minutes, respectively. 
The linearity was obtained in the range from 0.05 to 
30 µg ⋅ mL-1. The coefficient of variation for intra- and interday 
assays was less than 5%. The average recovery of probucol 
from plasma was between 98.6% and 101.4%.
Data analysis
The pharmacokinetics’ parameters were calculated by   
DAS 2.0 (issued by the State Food and Drug Administration 
of China for Pharmokinetic Study). Student’s t-tests were 
performed to evaluate the significant differences. Values are 
reported as Mean ±   standard deviation, and the data were 
considered statistically significant at P , 0.05.
Results and discussion
SMEDDS formulation
In our pseudoternary phase diagram study (Figure 1), systems 
consisting of olive oil and Lauroglycol FCC as oil phase, 
Cremophor EL and Tween-80 as emulsifiers, and PEG-400 
as coemulsifier were titrated with water, and self-emulsifying 
formulations were selected from regions undergoing infinite 
dilution. In the diagrams (Figure 1A–D), with the decrease of 
olive oil/Lauroglycol FCC ratio, the area of self-microemul-
sifying region increased. When the Cremophor EL/Tween-80 
ratio increased, the area of self-microemulsifying region 
increased (Figure 1D and E). Diagrams with higher emul-
sifier/co-emulsifier ratio had larger self-microemulsifying 
area   (Figure 1D, F, G). The optimal formulation of probucol 
SMEDDS was selected to investigate the self-microemulsify-
ing ability, solubilization ability, and reduced use of emulsi-
fiers, was as follows: olive oil (13%, w/w), Lauroglycol FCC 
(27%, w/w), Cremophor EL (20%, w/w), Tween-80 (20%, 
w/w), and PEG-400 (20%, w/w). Sixty milligrams of probucol 
was dissolved in 1 g of mixture.
Droplet size
Droplet size after microemulsification was the most 
important property of SMEDDS. It may affect the release 
and absorption of drug in GI tract.14,15 The typical size 
distribution is shown in Figure 2. It seemed that dilution 
volume within the investigated range and different dilution 
media had little effect on droplet size (Figure 3) and self-
microemulsifying behavior (P . 0.05). The mean droplet 
size did not change significantly with increased drug loading 
(Figure 4; P . 0.05).
Morphology
Morphology of the microemulsions formed from SMEDDS 
was viewed under a TEM, the microemulsion vesicles 
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appeared as perfect round shapes without aggregation 
(Figure 5).
Dissolution studies
Our previous study showed probucol was practically insoluble 
in water at acidic or neutral pH. As shown in   Figure 6, crude 
probucol showed negligible release even after 60   minutes 
in both PBS (pH 7.0) and 0.1 M hydrochloride solution. 
Whereas, SMEDDS showed rapid dissolution in both solu-
tions, at 10 minute about 80% of probucol from SMEDDS 
was dissolved in medium, and more than 90% was released 
after 20 minutes. SMEDDS could form clear and transparent 
solution in the condition of dissolution quickly.
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Figure 1 Pseudoternary phase diagrams of different composition of oil phase, emulsifiers, and coemulsifiers. 
Note: The dark regions represent the microemulsion phase.
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Figure 2 Size distribution of probucol self-microemulsifying drug-delivery system determined by laser diffraction sizer after dilution to deionized water.
Abbreviations: REL, relative; Intens-wt, intensive weight; Auto B adj, automatic B adjust; Ch 1 data, channel 1 data; Z-average diff coeff, Z-average difference coefficient; PI, 
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Bioavailability study
The pharmacokinetic parameters of probucol SMEDDS, oil 
solution, and suspension were compared in rats. Mean plasma 
probucol concentration was plotted as a function of time 
(Figure 7).
The pharmacokinetic parameters of SMEDDS, oil solu-
tion, and suspension are shown in Table 1. As can be seen, 
the maximum concentration (Cmax) of probucol SMEDDS 
was 3.36 ± 0.84 µg ⋅ mL-1, compared with those of oil solu-
tion and suspension which were 1.80 ± 0.43 µg ⋅ mL-1 and 
0.16 ± 0.07 µg ⋅ mL-1, respectively. Statistically, the differ-
ences in Cmax of probucol SMEDDS were extremely signifi-
cant (P , 0.01) when compared with Cmax of oil   solution 
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(P , 0.01) and suspension (P , 0.001). It was also observed 
that the area under the curve (AUC0–120 hours) of SMEDDS was 
73.59 ± 31.21 µg ⋅ mL-1 ⋅ hour, and thus the difference was 
highly significant compared with that of the oil solution (
34.16 ± 10.65 µg ⋅ mL-1 ⋅ hour) (P , 0.02) and suspension 
(7.20 ± 1.63 µg ⋅ mL-1 ⋅ hour) (P , 0.001). The bioavailability 
of SMEDDS was 2.15- and 10.22-fold that of oil solution 
and suspension, respectively.
Lipid-based formulations such as oil solution and self-
microemulsifying drug-delivery systems offer the potential 
for enhancing the absorption and hence the oral bioavail-
ability of lipophilic drugs. The primary mechanisms are 
presenting the drug in solubilized form in vivo, delaying 
gastric emptying, increasing mucosal permeability, and 
increasing incorporation into lipoproteins, then secreted into 
the lymphatics, which circumvents the liver, thus reducing 
the hepatic first-pass metabolism.14,16–18
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Figure 5 Transmission electron microscopy of probucol microemulsion at the 
dilution of 1:50 in deionized water.
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It was reported that probucol had high lymphatic bioavail-
ability when coadministrated with lipids.19,20   Chylomicrons 
(CMs) are important in drug delivery since many lipophilic 
drugs are carried by CMs and transported in lymph.21 Palin 
and Wilson reported that digestion of oil within the small 
intestine resulted in the liberation of long-chain fatty acids, 
which effectively promoted chylomicron formation and con-
sequently the lymphatic transport of DDT or probucol.19
Enhancement of bioavailability of probucol SMEDDS 
compared with oil solution may be due to effects of a large 
quantity of surfactants and cosurfactant, including improved 
mucosal permeability, smaller lipid droplets and greater 
surface area. In addition, it was reported that Tween-80 
can promote CMs secretion and counteracted the inhibitory 
effects of other surfactants.22
Double peaks of Cmax were observed after administration 
of SMEDDS. This may be caused by protection effects of 
surfactants for lipid from digestion, high lymphatic bioavail-
ability of probucol, and the slow flow rate of lymph. It has 
been proven that the presence of digestion products such 
as monoglycerides and fatty acids, incorporated in bile salt 
micelles, increases the solubility of poorly water-soluble 
drugs and therefore can enhance their absorption. With 
digestion proceeding and the oil phase breaking down, the 
surfactant and fatty acids will spread out into the release 
medium, which causes the drug to release.23,24 Surfactants 
located at the oil droplet surface can interfere with the attach-
ment of the lipase complex to the oil–water interface and 
inhibit lipolysis of lipids.25–27
Conclusion
A SMEDDS formulation for probucol was developed, 
and the optimal formulation was as follows: olive oil 
(13%, w/w), Lauroglycol FCC (27%, w/w), Cremophor EL 
(20%, w/w), Tween-80 (20%, w/w), and PEG-400 (20%, 
w/w). When diluted with water, probucol-loaded SMEDDS 
could spontaneously form small particles with average drop-
let size of about 80 nm. Different media, dilution volume 
and drug loading seemed to have no effect on droplet size 
and self-microemulsifying behavior. Dissolution percent-
ages of probucol in SMEDDS in 0.1 M HCl or in pH 7.0 
PBS were significantly higher than that of crude probucol. 
Relative bioavailability of probucol SMEDDS was dramati-
cally enhanced, approximately 2.15- and 10.22-fold that of 
olive oil solution and suspension, respectively. Our studies 
illustrated the potential use of SMEDDS for the delivery of 
hydrophobic compounds, such as probucol.
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